Munich (Germany), March 03, 2015: ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, announced today its participation at Sachs European Life Science CEO Forum and Exhibition taking place in Zurich, Switzerland, on March 3-4, 2015.
Dr. Bernard Huber, CEO and Founder of ORYX, will present at 11:15 am (CET) on March 4, 2015 in Room Panorama C. At Sachs European Life Science CEO Forum and Exhibition, around 80 companies from Europe and the US will present to leading investors, pharma companies and scientific thought leaders.
About ORYX:
ORYX is a privately held Munich based biotech company. ORYX develops three highly innovative drug candidates for the treatment of cancer, originating from leading research institutions like the German Cancer Research Center (DKFZ) and the University of Heidelberg. The ORYX clinical development portfolio consists of an oncolytic virus and two therapeutic cancer vaccines. ORYX holds exclusive, world-wide licenses for all its development projects. For more information please visit: www.oryx-medicine.com
For further information, please contact:
Dr. Bernard Huber
Chief Executive Officer
ORYX GmbH & Co. KG
Phone: +49-8106-21-311-0
Email: info@oryx-medicine.com
Business Development
Dr. Dr. Sven Rohmann
Phone: +49-8106-21-311-0
Mobile: +41-7957 78895
Email: info@oryx-medicine.com
PR/IR contact
Katja Arnold (CIRO)
Executive Director MC Services AG
Phone: +49-89-210-228-40
Email: katja.arnold@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.
